John D. Whalen
Slough, ENG SL13XE, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Corrigendum to "Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry" [Clinical Immunology 283 (2025) 110632].
Journal: Clinical immunology (Orlando, Fla.)
Published: June 09, 2026
Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome.
Journal: Frontiers in immunology
Published: November 04, 2025
Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry.
Journal: Clinical immunology (Orlando, Fla.)
Published: July 04, 2025
The Impact of Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) on Health-Related Quality of Life (HRQoL): Elicitation of Health State Utility Values Through Time Trade-Off (TTO) and EQ-5D.
Journal: Advances in therapy
Published: February 26, 2025
Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study.
Journal: Clinical and experimental immunology
Published: July 30, 2024
A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS).
Journal: Orphanet journal of rare diseases
Published: November 22, 2023
A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity.
Journal: Toxins
Published: July 18, 2023
Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Journal: Journal of medical economics
Published: January 17, 2023
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: August 26, 2022
Modelling Long-Term Outcomes and Risk of Death for Patients with Post-Stroke Spasticity Receiving Abobotulinumtoxina Treatment and Rehabilitation Therapy.
Journal: Journal of rehabilitation medicine
Published: July 18, 2022
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Journal: Journal of medical economics
Published: June 22, 2022
Last Updated: 09/26/2026